nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferiprone—Furuncle—Methotrexate—muscle cancer	0.00975	0.00975	CcSEcCtD
Deferiprone—Sepsis—Dactinomycin—muscle cancer	0.00957	0.00957	CcSEcCtD
Deferiprone—Myositis—Doxorubicin—muscle cancer	0.00845	0.00845	CcSEcCtD
Deferiprone—Furuncle—Doxorubicin—muscle cancer	0.00845	0.00845	CcSEcCtD
Deferiprone—Muscle relaxant therapy—Doxorubicin—muscle cancer	0.00832	0.00832	CcSEcCtD
Deferiprone—Hypotonia—Doxorubicin—muscle cancer	0.00788	0.00788	CcSEcCtD
Deferiprone—Aspartate aminotransferase increased—Dactinomycin—muscle cancer	0.00721	0.00721	CcSEcCtD
Deferiprone—Pain in extremity—Vincristine—muscle cancer	0.00716	0.00716	CcSEcCtD
Deferiprone—Gastric ulcer—Doxorubicin—muscle cancer	0.00713	0.00713	CcSEcCtD
Deferiprone—Sepsis—Etoposide—muscle cancer	0.00693	0.00693	CcSEcCtD
Deferiprone—Optic neuritis—Doxorubicin—muscle cancer	0.00673	0.00673	CcSEcCtD
Deferiprone—Thrombocytosis—Doxorubicin—muscle cancer	0.00666	0.00666	CcSEcCtD
Deferiprone—Dehydration—Vincristine—muscle cancer	0.00665	0.00665	CcSEcCtD
Deferiprone—Pancytopenia—Dactinomycin—muscle cancer	0.00657	0.00657	CcSEcCtD
Deferiprone—Neutropenia—Dactinomycin—muscle cancer	0.00647	0.00647	CcSEcCtD
Deferiprone—Aspartate aminotransferase increased—Vincristine—muscle cancer	0.00644	0.00644	CcSEcCtD
Deferiprone—Pneumonia—Dactinomycin—muscle cancer	0.00621	0.00621	CcSEcCtD
Deferiprone—Cardiac failure—Etoposide—muscle cancer	0.00594	0.00594	CcSEcCtD
Deferiprone—Pancytopenia—Vincristine—muscle cancer	0.00587	0.00587	CcSEcCtD
Deferiprone—Hepatomegaly—Doxorubicin—muscle cancer	0.00585	0.00585	CcSEcCtD
Deferiprone—Nystagmus—Doxorubicin—muscle cancer	0.0058	0.0058	CcSEcCtD
Deferiprone—Neutropenia—Vincristine—muscle cancer	0.00578	0.00578	CcSEcCtD
Deferiprone—Agranulocytosis—Dactinomycin—muscle cancer	0.00576	0.00576	CcSEcCtD
Deferiprone—Photosensitivity reaction—Vincristine—muscle cancer	0.00565	0.00565	CcSEcCtD
Deferiprone—Haemoptysis—Doxorubicin—muscle cancer	0.0056	0.0056	CcSEcCtD
Deferiprone—Pneumonia—Vincristine—muscle cancer	0.00555	0.00555	CcSEcCtD
Deferiprone—Hepatitis—Dactinomycin—muscle cancer	0.00554	0.00554	CcSEcCtD
Deferiprone—Pharyngitis—Dactinomycin—muscle cancer	0.0055	0.0055	CcSEcCtD
Deferiprone—Rash pustular—Doxorubicin—muscle cancer	0.00519	0.00519	CcSEcCtD
Deferiprone—Alanine aminotransferase increased—Etoposide—muscle cancer	0.00511	0.00511	CcSEcCtD
Deferiprone—Glycosuria—Doxorubicin—muscle cancer	0.00511	0.00511	CcSEcCtD
Deferiprone—Chills—Dactinomycin—muscle cancer	0.00497	0.00497	CcSEcCtD
Deferiprone—Urinary tract disorder—Vincristine—muscle cancer	0.00489	0.00489	CcSEcCtD
Deferiprone—Connective tissue disorder—Vincristine—muscle cancer	0.00486	0.00486	CcSEcCtD
Deferiprone—Urethral disorder—Vincristine—muscle cancer	0.00485	0.00485	CcSEcCtD
Deferiprone—Pulmonary embolism—Methotrexate—muscle cancer	0.00478	0.00478	CcSEcCtD
Deferiprone—Pancytopenia—Etoposide—muscle cancer	0.00476	0.00476	CcSEcCtD
Deferiprone—Neutropenia—Etoposide—muscle cancer	0.00468	0.00468	CcSEcCtD
Deferiprone—Cardiac disorder—Vincristine—muscle cancer	0.00459	0.00459	CcSEcCtD
Deferiprone—Rectal haemorrhage—Doxorubicin—muscle cancer	0.00459	0.00459	CcSEcCtD
Deferiprone—Arthropathy—Doxorubicin—muscle cancer	0.00455	0.00455	CcSEcCtD
Deferiprone—Pneumonia—Etoposide—muscle cancer	0.00449	0.00449	CcSEcCtD
Deferiprone—Angiopathy—Vincristine—muscle cancer	0.00449	0.00449	CcSEcCtD
Deferiprone—Infestation—Etoposide—muscle cancer	0.00447	0.00447	CcSEcCtD
Deferiprone—Infestation NOS—Etoposide—muscle cancer	0.00447	0.00447	CcSEcCtD
Deferiprone—Mediastinal disorder—Vincristine—muscle cancer	0.00446	0.00446	CcSEcCtD
Deferiprone—Blood bilirubin increased—Doxorubicin—muscle cancer	0.00438	0.00438	CcSEcCtD
Deferiprone—Jaundice—Etoposide—muscle cancer	0.00435	0.00435	CcSEcCtD
Deferiprone—Mental disorder—Vincristine—muscle cancer	0.00434	0.00434	CcSEcCtD
Deferiprone—Gait disturbance—Doxorubicin—muscle cancer	0.00424	0.00424	CcSEcCtD
Deferiprone—Hepatobiliary disease—Etoposide—muscle cancer	0.00422	0.00422	CcSEcCtD
Deferiprone—Agranulocytosis—Etoposide—muscle cancer	0.00417	0.00417	CcSEcCtD
Deferiprone—Back pain—Vincristine—muscle cancer	0.00417	0.00417	CcSEcCtD
Deferiprone—Sepsis—Methotrexate—muscle cancer	0.00415	0.00415	CcSEcCtD
Deferiprone—Pulmonary embolism—Doxorubicin—muscle cancer	0.00414	0.00414	CcSEcCtD
Deferiprone—Discomfort—Dactinomycin—muscle cancer	0.00406	0.00406	CcSEcCtD
Deferiprone—Urinary tract disorder—Etoposide—muscle cancer	0.00396	0.00396	CcSEcCtD
Deferiprone—Urethral disorder—Etoposide—muscle cancer	0.00393	0.00393	CcSEcCtD
Deferiprone—Infection—Dactinomycin—muscle cancer	0.00391	0.00391	CcSEcCtD
Deferiprone—Eye disorder—Etoposide—muscle cancer	0.00375	0.00375	CcSEcCtD
Deferiprone—Convulsion—Vincristine—muscle cancer	0.00373	0.00373	CcSEcCtD
Deferiprone—Cardiac disorder—Etoposide—muscle cancer	0.00372	0.00372	CcSEcCtD
Deferiprone—Hypertension—Vincristine—muscle cancer	0.00372	0.00372	CcSEcCtD
Deferiprone—Angiopathy—Etoposide—muscle cancer	0.00364	0.00364	CcSEcCtD
Deferiprone—Immune system disorder—Etoposide—muscle cancer	0.00362	0.00362	CcSEcCtD
Deferiprone—Mediastinal disorder—Etoposide—muscle cancer	0.00361	0.00361	CcSEcCtD
Deferiprone—Chills—Etoposide—muscle cancer	0.0036	0.0036	CcSEcCtD
Deferiprone—Sepsis—Doxorubicin—muscle cancer	0.00359	0.00359	CcSEcCtD
Deferiprone—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.00359	0.00359	CcSEcCtD
Deferiprone—Anaphylactic shock—Vincristine—muscle cancer	0.00352	0.00352	CcSEcCtD
Deferiprone—Infection—Vincristine—muscle cancer	0.00349	0.00349	CcSEcCtD
Deferiprone—Osteoarthritis—Methotrexate—muscle cancer	0.00347	0.00347	CcSEcCtD
Deferiprone—Nervous system disorder—Vincristine—muscle cancer	0.00345	0.00345	CcSEcCtD
Deferiprone—Decreased appetite—Dactinomycin—muscle cancer	0.00342	0.00342	CcSEcCtD
Deferiprone—Hyperhidrosis—Vincristine—muscle cancer	0.0034	0.0034	CcSEcCtD
Deferiprone—Fatigue—Dactinomycin—muscle cancer	0.00339	0.00339	CcSEcCtD
Deferiprone—Back pain—Etoposide—muscle cancer	0.00338	0.00338	CcSEcCtD
Deferiprone—Pain—Dactinomycin—muscle cancer	0.00337	0.00337	CcSEcCtD
Deferiprone—Hypotension—Vincristine—muscle cancer	0.00329	0.00329	CcSEcCtD
Deferiprone—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00322	0.00322	CcSEcCtD
Deferiprone—Musculoskeletal discomfort—Vincristine—muscle cancer	0.0032	0.0032	CcSEcCtD
Deferiprone—Increased appetite—Doxorubicin—muscle cancer	0.0032	0.0032	CcSEcCtD
Deferiprone—Abdominal pain—Dactinomycin—muscle cancer	0.00311	0.00311	CcSEcCtD
Deferiprone—Body temperature increased—Dactinomycin—muscle cancer	0.00311	0.00311	CcSEcCtD
Deferiprone—Cardiac failure—Doxorubicin—muscle cancer	0.00308	0.00308	CcSEcCtD
Deferiprone—Decreased appetite—Vincristine—muscle cancer	0.00306	0.00306	CcSEcCtD
Deferiprone—Gastrointestinal disorder—Vincristine—muscle cancer	0.00304	0.00304	CcSEcCtD
Deferiprone—Fatigue—Vincristine—muscle cancer	0.00303	0.00303	CcSEcCtD
Deferiprone—Convulsion—Etoposide—muscle cancer	0.00302	0.00302	CcSEcCtD
Deferiprone—Hypertension—Etoposide—muscle cancer	0.00301	0.00301	CcSEcCtD
Deferiprone—Pain—Vincristine—muscle cancer	0.00301	0.00301	CcSEcCtD
Deferiprone—Pain in extremity—Doxorubicin—muscle cancer	0.00301	0.00301	CcSEcCtD
Deferiprone—Diplopia—Doxorubicin—muscle cancer	0.00301	0.00301	CcSEcCtD
Deferiprone—Osteoarthritis—Doxorubicin—muscle cancer	0.00301	0.00301	CcSEcCtD
Deferiprone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00295	0.00295	CcSEcCtD
Deferiprone—Pancreatitis—Methotrexate—muscle cancer	0.00294	0.00294	CcSEcCtD
Deferiprone—Discomfort—Etoposide—muscle cancer	0.00294	0.00294	CcSEcCtD
Deferiprone—Hypersensitivity—Dactinomycin—muscle cancer	0.0029	0.0029	CcSEcCtD
Deferiprone—Gastrointestinal pain—Vincristine—muscle cancer	0.00288	0.00288	CcSEcCtD
Deferiprone—Pancytopenia—Methotrexate—muscle cancer	0.00285	0.00285	CcSEcCtD
Deferiprone—Anaphylactic shock—Etoposide—muscle cancer	0.00285	0.00285	CcSEcCtD
Deferiprone—Infection—Etoposide—muscle cancer	0.00283	0.00283	CcSEcCtD
Deferiprone—Asthenia—Dactinomycin—muscle cancer	0.00282	0.00282	CcSEcCtD
Deferiprone—Neutropenia—Methotrexate—muscle cancer	0.00281	0.00281	CcSEcCtD
Deferiprone—Dehydration—Doxorubicin—muscle cancer	0.0028	0.0028	CcSEcCtD
Deferiprone—Body temperature increased—Vincristine—muscle cancer	0.00278	0.00278	CcSEcCtD
Deferiprone—Abdominal pain—Vincristine—muscle cancer	0.00278	0.00278	CcSEcCtD
Deferiprone—Skin disorder—Etoposide—muscle cancer	0.00277	0.00277	CcSEcCtD
Deferiprone—Hyperhidrosis—Etoposide—muscle cancer	0.00275	0.00275	CcSEcCtD
Deferiprone—Photosensitivity reaction—Methotrexate—muscle cancer	0.00274	0.00274	CcSEcCtD
Deferiprone—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.00271	0.00271	CcSEcCtD
Deferiprone—Diarrhoea—Dactinomycin—muscle cancer	0.00269	0.00269	CcSEcCtD
Deferiprone—Pneumonia—Methotrexate—muscle cancer	0.00269	0.00269	CcSEcCtD
Deferiprone—Infestation NOS—Methotrexate—muscle cancer	0.00268	0.00268	CcSEcCtD
Deferiprone—Infestation—Methotrexate—muscle cancer	0.00268	0.00268	CcSEcCtD
Deferiprone—Hypotension—Etoposide—muscle cancer	0.00266	0.00266	CcSEcCtD
Deferiprone—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.00265	0.00265	CcSEcCtD
Deferiprone—Hypersensitivity—Vincristine—muscle cancer	0.00259	0.00259	CcSEcCtD
Deferiprone—Pancreatitis—Doxorubicin—muscle cancer	0.00255	0.00255	CcSEcCtD
Deferiprone—Somnolence—Etoposide—muscle cancer	0.00253	0.00253	CcSEcCtD
Deferiprone—Hepatobiliary disease—Methotrexate—muscle cancer	0.00253	0.00253	CcSEcCtD
Deferiprone—Epistaxis—Methotrexate—muscle cancer	0.00252	0.00252	CcSEcCtD
Deferiprone—Asthenia—Vincristine—muscle cancer	0.00252	0.00252	CcSEcCtD
Deferiprone—Vomiting—Dactinomycin—muscle cancer	0.0025	0.0025	CcSEcCtD
Deferiprone—Agranulocytosis—Methotrexate—muscle cancer	0.0025	0.0025	CcSEcCtD
Deferiprone—Rash—Dactinomycin—muscle cancer	0.00248	0.00248	CcSEcCtD
Deferiprone—Decreased appetite—Etoposide—muscle cancer	0.00248	0.00248	CcSEcCtD
Deferiprone—Pancytopenia—Doxorubicin—muscle cancer	0.00247	0.00247	CcSEcCtD
Deferiprone—Gastrointestinal disorder—Etoposide—muscle cancer	0.00246	0.00246	CcSEcCtD
Deferiprone—Fatigue—Etoposide—muscle cancer	0.00246	0.00246	CcSEcCtD
Deferiprone—Pain—Etoposide—muscle cancer	0.00244	0.00244	CcSEcCtD
Deferiprone—Neutropenia—Doxorubicin—muscle cancer	0.00243	0.00243	CcSEcCtD
Deferiprone—Diarrhoea—Vincristine—muscle cancer	0.00241	0.00241	CcSEcCtD
Deferiprone—Hepatitis—Methotrexate—muscle cancer	0.0024	0.0024	CcSEcCtD
Deferiprone—Pharyngitis—Methotrexate—muscle cancer	0.00238	0.00238	CcSEcCtD
Deferiprone—Urinary tract disorder—Methotrexate—muscle cancer	0.00237	0.00237	CcSEcCtD
Deferiprone—Photosensitivity reaction—Doxorubicin—muscle cancer	0.00237	0.00237	CcSEcCtD
Deferiprone—Weight increased—Doxorubicin—muscle cancer	0.00236	0.00236	CcSEcCtD
Deferiprone—Urethral disorder—Methotrexate—muscle cancer	0.00235	0.00235	CcSEcCtD
Deferiprone—Nausea—Dactinomycin—muscle cancer	0.00234	0.00234	CcSEcCtD
Deferiprone—Pneumonia—Doxorubicin—muscle cancer	0.00233	0.00233	CcSEcCtD
Deferiprone—Gastrointestinal pain—Etoposide—muscle cancer	0.00233	0.00233	CcSEcCtD
Deferiprone—Infestation NOS—Doxorubicin—muscle cancer	0.00232	0.00232	CcSEcCtD
Deferiprone—Infestation—Doxorubicin—muscle cancer	0.00232	0.00232	CcSEcCtD
Deferiprone—Urticaria—Etoposide—muscle cancer	0.00226	0.00226	CcSEcCtD
Deferiprone—Jaundice—Doxorubicin—muscle cancer	0.00226	0.00226	CcSEcCtD
Deferiprone—Body temperature increased—Etoposide—muscle cancer	0.00225	0.00225	CcSEcCtD
Deferiprone—Abdominal pain—Etoposide—muscle cancer	0.00225	0.00225	CcSEcCtD
Deferiprone—Eye disorder—Methotrexate—muscle cancer	0.00224	0.00224	CcSEcCtD
Deferiprone—Vomiting—Vincristine—muscle cancer	0.00224	0.00224	CcSEcCtD
Deferiprone—Cardiac disorder—Methotrexate—muscle cancer	0.00223	0.00223	CcSEcCtD
Deferiprone—Rash—Vincristine—muscle cancer	0.00222	0.00222	CcSEcCtD
Deferiprone—Dermatitis—Vincristine—muscle cancer	0.00222	0.00222	CcSEcCtD
Deferiprone—Headache—Vincristine—muscle cancer	0.0022	0.0022	CcSEcCtD
Deferiprone—Hepatobiliary disease—Doxorubicin—muscle cancer	0.00219	0.00219	CcSEcCtD
Deferiprone—Epistaxis—Doxorubicin—muscle cancer	0.00219	0.00219	CcSEcCtD
Deferiprone—Angiopathy—Methotrexate—muscle cancer	0.00218	0.00218	CcSEcCtD
Deferiprone—Immune system disorder—Methotrexate—muscle cancer	0.00217	0.00217	CcSEcCtD
Deferiprone—Mediastinal disorder—Methotrexate—muscle cancer	0.00216	0.00216	CcSEcCtD
Deferiprone—Agranulocytosis—Doxorubicin—muscle cancer	0.00216	0.00216	CcSEcCtD
Deferiprone—Chills—Methotrexate—muscle cancer	0.00216	0.00216	CcSEcCtD
Deferiprone—Mental disorder—Methotrexate—muscle cancer	0.0021	0.0021	CcSEcCtD
Deferiprone—Hypersensitivity—Etoposide—muscle cancer	0.0021	0.0021	CcSEcCtD
Deferiprone—Malnutrition—Methotrexate—muscle cancer	0.00209	0.00209	CcSEcCtD
Deferiprone—Nausea—Vincristine—muscle cancer	0.00209	0.00209	CcSEcCtD
Deferiprone—Hepatitis—Doxorubicin—muscle cancer	0.00208	0.00208	CcSEcCtD
Deferiprone—Pharyngitis—Doxorubicin—muscle cancer	0.00206	0.00206	CcSEcCtD
Deferiprone—Urinary tract disorder—Doxorubicin—muscle cancer	0.00205	0.00205	CcSEcCtD
Deferiprone—Oedema peripheral—Doxorubicin—muscle cancer	0.00205	0.00205	CcSEcCtD
Deferiprone—Asthenia—Etoposide—muscle cancer	0.00204	0.00204	CcSEcCtD
Deferiprone—Connective tissue disorder—Doxorubicin—muscle cancer	0.00204	0.00204	CcSEcCtD
Deferiprone—Urethral disorder—Doxorubicin—muscle cancer	0.00204	0.00204	CcSEcCtD
Deferiprone—Back pain—Methotrexate—muscle cancer	0.00202	0.00202	CcSEcCtD
Deferiprone—Pruritus—Etoposide—muscle cancer	0.00202	0.00202	CcSEcCtD
Deferiprone—Diarrhoea—Etoposide—muscle cancer	0.00195	0.00195	CcSEcCtD
Deferiprone—Eye disorder—Doxorubicin—muscle cancer	0.00194	0.00194	CcSEcCtD
Deferiprone—Cardiac disorder—Doxorubicin—muscle cancer	0.00193	0.00193	CcSEcCtD
Deferiprone—Angiopathy—Doxorubicin—muscle cancer	0.00189	0.00189	CcSEcCtD
Deferiprone—Immune system disorder—Doxorubicin—muscle cancer	0.00188	0.00188	CcSEcCtD
Deferiprone—Mediastinal disorder—Doxorubicin—muscle cancer	0.00187	0.00187	CcSEcCtD
Deferiprone—Chills—Doxorubicin—muscle cancer	0.00187	0.00187	CcSEcCtD
Deferiprone—Mental disorder—Doxorubicin—muscle cancer	0.00182	0.00182	CcSEcCtD
Deferiprone—Convulsion—Methotrexate—muscle cancer	0.00181	0.00181	CcSEcCtD
Deferiprone—Vomiting—Etoposide—muscle cancer	0.00181	0.00181	CcSEcCtD
Deferiprone—Malnutrition—Doxorubicin—muscle cancer	0.00181	0.00181	CcSEcCtD
Deferiprone—Rash—Etoposide—muscle cancer	0.0018	0.0018	CcSEcCtD
Deferiprone—Dermatitis—Etoposide—muscle cancer	0.00179	0.00179	CcSEcCtD
Deferiprone—Headache—Etoposide—muscle cancer	0.00178	0.00178	CcSEcCtD
Deferiprone—Arthralgia—Methotrexate—muscle cancer	0.00178	0.00178	CcSEcCtD
Deferiprone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.00177	0.00177	CcSEcCtD
Deferiprone—Discomfort—Methotrexate—muscle cancer	0.00176	0.00176	CcSEcCtD
Deferiprone—Back pain—Doxorubicin—muscle cancer	0.00175	0.00175	CcSEcCtD
Deferiprone—Anaphylactic shock—Methotrexate—muscle cancer	0.00171	0.00171	CcSEcCtD
Deferiprone—Infection—Methotrexate—muscle cancer	0.0017	0.0017	CcSEcCtD
Deferiprone—Nausea—Etoposide—muscle cancer	0.00169	0.00169	CcSEcCtD
Deferiprone—Nervous system disorder—Methotrexate—muscle cancer	0.00167	0.00167	CcSEcCtD
Deferiprone—Skin disorder—Methotrexate—muscle cancer	0.00166	0.00166	CcSEcCtD
Deferiprone—Hyperhidrosis—Methotrexate—muscle cancer	0.00165	0.00165	CcSEcCtD
Deferiprone—Hypotension—Methotrexate—muscle cancer	0.00159	0.00159	CcSEcCtD
Deferiprone—Convulsion—Doxorubicin—muscle cancer	0.00157	0.00157	CcSEcCtD
Deferiprone—Hypertension—Doxorubicin—muscle cancer	0.00156	0.00156	CcSEcCtD
Deferiprone—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.00155	0.00155	CcSEcCtD
Deferiprone—Arthralgia—Doxorubicin—muscle cancer	0.00154	0.00154	CcSEcCtD
Deferiprone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.00153	0.00153	CcSEcCtD
Deferiprone—Discomfort—Doxorubicin—muscle cancer	0.00152	0.00152	CcSEcCtD
Deferiprone—Somnolence—Methotrexate—muscle cancer	0.00152	0.00152	CcSEcCtD
Deferiprone—Dyspepsia—Methotrexate—muscle cancer	0.0015	0.0015	CcSEcCtD
Deferiprone—Decreased appetite—Methotrexate—muscle cancer	0.00148	0.00148	CcSEcCtD
Deferiprone—Anaphylactic shock—Doxorubicin—muscle cancer	0.00148	0.00148	CcSEcCtD
Deferiprone—Gastrointestinal disorder—Methotrexate—muscle cancer	0.00147	0.00147	CcSEcCtD
Deferiprone—Fatigue—Methotrexate—muscle cancer	0.00147	0.00147	CcSEcCtD
Deferiprone—Infection—Doxorubicin—muscle cancer	0.00147	0.00147	CcSEcCtD
Deferiprone—Pain—Methotrexate—muscle cancer	0.00146	0.00146	CcSEcCtD
Deferiprone—Nervous system disorder—Doxorubicin—muscle cancer	0.00145	0.00145	CcSEcCtD
Deferiprone—Skin disorder—Doxorubicin—muscle cancer	0.00144	0.00144	CcSEcCtD
Deferiprone—Hyperhidrosis—Doxorubicin—muscle cancer	0.00143	0.00143	CcSEcCtD
Deferiprone—Gastrointestinal pain—Methotrexate—muscle cancer	0.0014	0.0014	CcSEcCtD
Deferiprone—Hypotension—Doxorubicin—muscle cancer	0.00138	0.00138	CcSEcCtD
Deferiprone—Urticaria—Methotrexate—muscle cancer	0.00136	0.00136	CcSEcCtD
Deferiprone—Body temperature increased—Methotrexate—muscle cancer	0.00135	0.00135	CcSEcCtD
Deferiprone—Abdominal pain—Methotrexate—muscle cancer	0.00135	0.00135	CcSEcCtD
Deferiprone—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.00135	0.00135	CcSEcCtD
Deferiprone—Somnolence—Doxorubicin—muscle cancer	0.00131	0.00131	CcSEcCtD
Deferiprone—Dyspepsia—Doxorubicin—muscle cancer	0.0013	0.0013	CcSEcCtD
Deferiprone—Decreased appetite—Doxorubicin—muscle cancer	0.00128	0.00128	CcSEcCtD
Deferiprone—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.00128	0.00128	CcSEcCtD
Deferiprone—Fatigue—Doxorubicin—muscle cancer	0.00127	0.00127	CcSEcCtD
Deferiprone—Pain—Doxorubicin—muscle cancer	0.00126	0.00126	CcSEcCtD
Deferiprone—Hypersensitivity—Methotrexate—muscle cancer	0.00126	0.00126	CcSEcCtD
Deferiprone—Asthenia—Methotrexate—muscle cancer	0.00122	0.00122	CcSEcCtD
Deferiprone—Gastrointestinal pain—Doxorubicin—muscle cancer	0.00121	0.00121	CcSEcCtD
Deferiprone—Pruritus—Methotrexate—muscle cancer	0.00121	0.00121	CcSEcCtD
Deferiprone—Urticaria—Doxorubicin—muscle cancer	0.00117	0.00117	CcSEcCtD
Deferiprone—Abdominal pain—Doxorubicin—muscle cancer	0.00117	0.00117	CcSEcCtD
Deferiprone—Body temperature increased—Doxorubicin—muscle cancer	0.00117	0.00117	CcSEcCtD
Deferiprone—Diarrhoea—Methotrexate—muscle cancer	0.00117	0.00117	CcSEcCtD
Deferiprone—Hypersensitivity—Doxorubicin—muscle cancer	0.00109	0.00109	CcSEcCtD
Deferiprone—Vomiting—Methotrexate—muscle cancer	0.00109	0.00109	CcSEcCtD
Deferiprone—Rash—Methotrexate—muscle cancer	0.00108	0.00108	CcSEcCtD
Deferiprone—Dermatitis—Methotrexate—muscle cancer	0.00108	0.00108	CcSEcCtD
Deferiprone—Headache—Methotrexate—muscle cancer	0.00107	0.00107	CcSEcCtD
Deferiprone—Asthenia—Doxorubicin—muscle cancer	0.00106	0.00106	CcSEcCtD
Deferiprone—Pruritus—Doxorubicin—muscle cancer	0.00105	0.00105	CcSEcCtD
Deferiprone—Nausea—Methotrexate—muscle cancer	0.00101	0.00101	CcSEcCtD
Deferiprone—Diarrhoea—Doxorubicin—muscle cancer	0.00101	0.00101	CcSEcCtD
Deferiprone—Vomiting—Doxorubicin—muscle cancer	0.00094	0.00094	CcSEcCtD
Deferiprone—Rash—Doxorubicin—muscle cancer	0.000932	0.000932	CcSEcCtD
Deferiprone—Dermatitis—Doxorubicin—muscle cancer	0.000931	0.000931	CcSEcCtD
Deferiprone—Headache—Doxorubicin—muscle cancer	0.000926	0.000926	CcSEcCtD
Deferiprone—Nausea—Doxorubicin—muscle cancer	0.000878	0.000878	CcSEcCtD
